12633795

Source:http://linkedlifedata.com/resource/pubmed/id/12633795

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008976, umls-concept:C0024027, umls-concept:C0027996, umls-concept:C0074554, umls-concept:C0178602, umls-concept:C0220825, umls-concept:C0286651, umls-concept:C0450442, umls-concept:C1121704, umls-concept:C1442989, umls-concept:C1510823, umls-concept:C1707455
pubmed:issue	6
pubmed:dateCreated	2003-3-13
pubmed:abstractText	This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with a special emphasis on relative starting doses. Subjects (n = 315) with elevated low-density lipoprotein (LDL) cholesterol and decreased high-density lipoprotein (HDL) cholesterol blood levels (defined as LDL cholesterol blood levels > or =160 mg/dl without coronary artery disease, or > or =130 mg/dl if coronary artery disease was present, and HDL cholesterol <45 mg/dl in men and <50 mg/dl in women) were randomized to atorvastatin, simvastatin, or niacin ER/lovastatin for 16 weeks. The primary efficacy variables were the mean percent change in LDL cholesterol and HDL cholesterol levels from baseline. After 8 weeks, the starting dose niacin ER/lovastatin 1,000/40 mg and the 10-mg starting dose atorvastatin both lowered mean LDL cholesterol by 38%. After 12 weeks, niacin ER/lovastatin 1,000/40 mg lowered LDL cholesterol by 42% versus 34% with the 20-mg starting dose of simvastatin (p <0.001). Niacin ER/lovastatin increased HDL cholesterol significantly more than atorvastatin or simvastatin at all compared doses (p <0.001). Niacin ER/lovastatin also provided significant improvements in triglycerides, lipoprotein(a), apolipoprotein A-1, apolipoprotein B, and HDL subfractions. A total of 6% of study subjects receiving niacin ER/lovastatin withdrew because of flushing. No significant differences were seen among study groups in discontinuance due to elevated liver enzymes. No drug-induced myopathy was observed. Niacin ER/lovastatin was comparable to atorvastatin 10 mg and more effective than simvastatin 20 mg in reducing LDL cholesterol, was more effective in increasing HDL cholesterol than either atorvastatin or simvastatin, and provided greater global improvements in non-HDL cholesterol, triglycerides, and lipoprotein(a).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0207277
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Anticholesteremic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations, http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations, http://linkedlifedata.com/resource/pubmed/chemical/Heptanoic Acids, http://linkedlifedata.com/resource/pubmed/chemical/Hypolipidemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Lipids, http://linkedlifedata.com/resource/pubmed/chemical/Lovastatin, http://linkedlifedata.com/resource/pubmed/chemical/Niacin, http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles, http://linkedlifedata.com/resource/pubmed/chemical/Simvastatin, http://linkedlifedata.com/resource/pubmed/chemical/atorvastatin, http://linkedlifedata.com/resource/pubmed/chemical/lovastatin-niacin combination
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	0002-9149
pubmed:author	pubmed-author:ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation, pubmed-author:BaysHarold EHE, pubmed-author:CrouseJohn RJR, pubmed-author:DujovneCarlos ACA, pubmed-author:HutchesonA GeneAG, pubmed-author:KashyapMoti LML, pubmed-author:McGovernMark EME, pubmed-author:WhiteT EricTE
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	91
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	667-72
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:12633795-Adolescent, pubmed-meshheading:12633795-Adult, pubmed-meshheading:12633795-Aged, pubmed-meshheading:12633795-Anticholesteremic Agents, pubmed-meshheading:12633795-Delayed-Action Preparations, pubmed-meshheading:12633795-Dose-Response Relationship, Drug, pubmed-meshheading:12633795-Drug Combinations, pubmed-meshheading:12633795-Female, pubmed-meshheading:12633795-Follow-Up Studies, pubmed-meshheading:12633795-Heptanoic Acids, pubmed-meshheading:12633795-Humans, pubmed-meshheading:12633795-Hyperlipidemias, pubmed-meshheading:12633795-Hypolipidemic Agents, pubmed-meshheading:12633795-Lipids, pubmed-meshheading:12633795-Lovastatin, pubmed-meshheading:12633795-Male, pubmed-meshheading:12633795-Middle Aged, pubmed-meshheading:12633795-Niacin, pubmed-meshheading:12633795-Pyrroles, pubmed-meshheading:12633795-Simvastatin, pubmed-meshheading:12633795-Time Factors
pubmed:year	2003
pubmed:articleTitle	Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
pubmed:affiliation	Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study